Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03722407 · OUTCOME

Time to Acute Myeloid Leukemia (AML) Transformation

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
Every 6 months after conclusion of treatment until end of study (40.3 months)

What was measured

Time to AML transformation according to World Health Organization (WHO) Critieria

Analysis population: Participants who had AML transformation

Groups in this outcome

Ruxolitinib

All patients will be given their first dose of oral Ruxolitinib, 20 mg at first scheduled visit. After that dose and on all other days patients will self-administer oral Ruxolitinib at a dose of 40 mg daily divided into two equal doses approximately 12 hours apart. Patients will be treated for a total of 16 weeks. After treatment, patients will be followed monthly. Ruxolitinib: Ruxolitinib 5 mg tablets, 4 per dose

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ruxolitinib8

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Ruxolitinib5.0Not reported1.240.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.2
        upper Limit
        40.3
        value
        5.0
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    units
    Participants
description
Time to AML transformation according to World Health Organization (WHO) Critieria
dispersion Type
Full Range
groups
  1. description
    All patients will be given their first dose of oral Ruxolitinib, 20 mg at first scheduled visit. After that dose and on all other days patients will self-administer oral Ruxolitinib at a dose of 40 mg daily divided into two equal doses approximately 12 hours apart. Patients will be treated for a total of 16 weeks. After treatment, patients will be followed monthly. Ruxolitinib: Ruxolitinib 5 mg tablets, 4 per dose
    id
    OG000
    title
    Ruxolitinib
param Type
MEDIAN
population Description
Participants who had AML transformation
reporting Status
POSTED
time Frame
Every 6 months after conclusion of treatment until end of study (40.3 months)
title
Time to Acute Myeloid Leukemia (AML) Transformation
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice